UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reply to: ‘Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action’

Journal of viral hepatitis, 2021-04, Vol.28 (4), p.689-690

2021

Volltextzugriff (PDF)

What drives the dynamics of HBV RNA during treatment?

Journal of viral hepatitis, 2021-02, Vol.28 (2), p.383-392

2021

Volltextzugriff (PDF)

Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B

Hepatology (Baltimore, Md.), 2021-10, Vol.74 (4), p.1795-1808

2021

Volltextzugriff (PDF)

Novel modelling approaches to predict the role of antivirals in reducing influenza transmission

PLoS computational biology, 2023-01, Vol.19 (1), p.e1010797

2023

Volltextzugriff (PDF)

A Semi‐mechanistic Model to Characterize the Long‐Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon

Clinical pharmacology and therapeutics, 2023-02, Vol.113 (2), p.390-400

2023

Volltextzugriff (PDF)

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

Clinical pharmacology and therapeutics, 2021-04, Vol.109 (4), p.1081-1091

2021

Volltextzugriff (PDF)

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.1189-1201

2022

Volltextzugriff (PDF)

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

British journal of clinical pharmacology, 2021-03, Vol.87 (3), p.1359-1368

2021

Volltextzugriff (PDF)

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas

Pediatric blood & cancer, 2018-02, Vol.65 (2), p.n/a

2018

Volltextzugriff (PDF)

Epidemiological Agent-Based Modelling Software (Epiabm)

Journal of open research software, 2024-03, Vol.12 (1), p.3-3

2024

Volltextzugriff (PDF)

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa‐2a dosing regimen for children with hepatitis C

British journal of clinical pharmacology, 2016-04, Vol.81 (4), p.658-666

2016

Volltextzugriff (PDF)

The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine

Drug development research, 2014-03, Vol.75 (2), p.107-113

2014

Volltextzugriff (PDF)

Evaluation of uncertainty parameters estimated by different population PK software and methods

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.289-311

2007

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

Model Averaging in Viral Dynamic Models

The AAPS journal, 2020-02, Vol.22 (2), p.48, Article 48

2020

Volltextzugriff (PDF)

Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment

Clinical infectious diseases, 2022-02, Vol.74 (3), p.532-540

2022

Volltextzugriff (PDF)

FRI-173-Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir

Journal of hepatology, 2019-04, Vol.70 (1), p.e465-e465

2019

Volltextzugriff (PDF)

A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom

Expert review of pharmacoeconomics & outcomes research, 2024-09, Vol.24 (8), p.953-966

2024

Volltextzugriff (PDF)

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

The lancet. Gastroenterology & hepatology, 2021-09, Vol.6 (9), p.723-732

2021

Volltextzugriff (PDF)

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic hepatitis C virus infection with a non-nucleoside polymerase inhibitor

Antiviral therapy, 2018-01, Vol.23 (4), p.353-361

2018

Volltextzugriff (PDF)

A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression

Antimicrobial agents and chemotherapy, 2015-09, Vol.59 (9), p.5388-5395

2015

Volltextzugriff (PDF)

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor

Antiviral therapy, 2018-01, Vol.23 (4), p.353-361

2018

Volltextzugriff (PDF)

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Clinical pharmacokinetics, 2007-01, Vol.46 (3), p.221-234

2007

Volltextzugriff (PDF)

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

Antimicrobial agents and chemotherapy, 2016-03, Vol.60 (3), p.1953-1953

2016

Volltextzugriff (PDF)

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV

Antiviral therapy, 2015-01, Vol.20 (5), p.469-477

2015

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Pharmacology & Pharmacy
(16)
Humans
(15)
Pharmacokinetics
(9)
Antiviral Agents - Therapeutic Use
(7)
Infectious Diseases
(7)
Models, Biological
(7)
Life Sciences
(6)
Virology
(5)
Antiviral Agents - Pharmacokinetics
(4)
Gastroenterology & Hepatology
(4)
Adolescent
(3)
Adult
(3)
Animals
(3)
Antiviral Agents
(3)
Antiviral Agents - Administration & Dosage
(3)
Antiviral Agents - Pharmacology
(3)
Clinical Trials
(3)
Computer Simulation
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reply to: ‘Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action’

What drives the dynamics of HBV RNA during treatment?

Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B

Novel modelling approaches to predict the role of antivirals in reducing influenza transmission

A Semi‐mechanistic Model to Characterize the Long‐Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas

Epidemiological Agent-Based Modelling Software (Epiabm)

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa‐2a dosing regimen for children with hepatitis C

The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine

Evaluation of uncertainty parameters estimated by different population PK software and methods

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

Model Averaging in Viral Dynamic Models

Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment

FRI-173-Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir

A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic hepatitis C virus infection with a non-nucleoside polymerase inhibitor

A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV

Suchergebnisse filtern